Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity raises target price on Hochschild Mining

(Sharecast News) - Analysts at Canaccord Genuity raised their target price on precious metals exploration group Hochschild Mining from 285.0p to 370.0p on Thursday as gold and silver prices continued to surge. Canaccord Genuity said that with the gold price now up over 25% year-to-date, it has now passed through its most recent commodity price revisions.

"With our gold price revisions up 10-13% from 2025 to 2030 and our LT price up another 11%, we see substantial upside for HOC. We have increased our HOC 2025 and 2026 EBITDA forecasts by 17% and 15%, respectively. However, with the current spot price over US$3,300/oz, there is even further potential upside to our 2025 gold price forecast of US$3,024/oz," said Canaccord Genuity.

The Canadian bank, which has a 'buy' rating on the stock, believes the excess cash flows generated on the back of rising precious metals prices will leave Hochschild's balance sheet in a strong position by year-end 2025, with only $12.0m of net debt now forecast.

With Hochschild now forecast to move into a net cash position in early 2026 on its numbers, Canaccord sees excess cash flow both for potential early-stage funding of its MDC project in Brazil and further shareholder returns.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.